MIF作为生物标志物和治疗靶点用于克服人骨髓瘤对蛋白酶体抑制剂的耐药
本研究探讨巨噬细胞移动抑制因子(MIF)在多发骨髓瘤(MM)对蛋白酶体抑制剂(PI)耐药中的作用。复发患者纯化MM细胞MIF表达显著高于持续缓解者,高MIF患者无进展生存期和总生存期显著缩短。MIF通过维持线粒体功能保护MM细胞免于PI诱导凋亡,抑制MIF活性可在体内与PI协同并重新致敏耐药细胞。
要点
- 复发MM患者纯化MM细胞MIF表达显著高于持续缓解患者。
- 高MIF表达MM患者无进展生存期和总生存期显著缩短。
- 抑制MIF活性在体内与PI协同并重新致敏PI耐药MM细胞。
核心结论
- MIF在MM对PI的敏感性中起关键作用,靶向MIF可能是(重新)致敏MM对PI治疗的有前景策略。
研究设计与样本
- 研究比较了复发患者与持续缓解患者纯化MM细胞的MIF表达,使用MM细胞系进行MIF敲除和机制研究,并在体内评估MIF抑制剂与PI的联合作用。
主要发现
- 复发患者纯化MM细胞MIF表达显著高于持续缓解患者,高MIF患者无进展生存期和总生存期显著缩短。
- MM细胞系高表达MIF,敲除MIF使其对PI诱导凋亡更敏感,而其他化疗药物未观察到此现象。
- MIF以同源三聚体形式作为超氧化物歧化酶1(SOD1)的伴侣蛋白,抑制PI诱导的SOD1错误折叠并维持SOD1活性。
- MIF抑制剂4-碘-6-苯基嘧啶和同源三聚体破坏剂ebselen不杀伤MM细胞,但增强PI诱导的SOD1错误折叠和功能丧失,导致细胞系和原代MM细胞死亡显著增加。
- 体内抑制MIF活性显示与PI协同抗肿瘤活性,并重新致敏PI耐药MM细胞对治疗的反应。
关键数值与推荐
- 基因表达谱数据显示MIF与SOD1表达及MM患者对PI治疗反应之间呈显著负相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) remains largely incurable despite significant advances in biotherapy and chemotherapy. The development of drug resistance is a major problem in MM management. Macrophage migration inhibitory factor (MIF) expression was significantly higher in purified MM cells from relapsed patients than those with sustained response, and MM patients with high MIF had significantly shorter progression-free survival (PFS) and overall survival (OS). MM cell lines also express high levels of MIF, and knocking out MIF made them more sensitive to proteasome inhibitor (PI)-induced apoptosis not observed with other chemotherapy drugs. Mechanistic studies showed that MIF protects MM cells from PI-induced apoptosis by maintaining mitochondrial function via suppression of superoxide production in response to PIs. Specifically, MIF, in the form of a homotrimer, acts as a chaperone for superoxide dismutase 1 (SOD1) to suppress PI-induced SOD1 misfolding and to maintain SOD1 activity. MIF inhibitor 4-iodo-6-phenylpyrimidine and homotrimer disrupter ebselen, which do not kill MM cells, enhanced PI-induced SOD1 misfolding and loss of function, resulting in significantly more cell death in both cell lines and primary MM cells. More importantly, inhibiting MIF activity in vivo displayed synergistic antitumor activity with PIs and resensitized PI-resistant MM cells to treatment. In support of these findings, gene-profiling data showed a significantly negative correlation between MIF and SOD1 expression and response to PI treatment in patients with MM. This study shows that MIF plays a crucial role in MM sensitivity to PIs and suggests that targeting MIF may be a promising strategy to (re)sensitize MM to the treatment.
引用
- Wang Q, Zhao D, Xian M, et al. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood. 2020. PMID: 32582913. doi:10.1182/blood.2020005795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。